Dublin, March 04, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/97bx43/global) has announced the addition of the "Global Dermatophytic Onychomycosis Market 2016-2020" report to their offering.

The global dermatophytic onychomycosis market is expected to grow at a CAGR of 7.44% during the period 2016-2020.

According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.

It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone.

Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.

Key vendors:

• Anacor Pharmaceuticals
• Galderma
• Janssen Biotech
• Novartis
• Valeant Pharmaceuticals
  

Key questions answered in this report:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Overview: Dermatophytic onychomycosis

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by route of administration

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

Companies Mentioned:

• Anacor Pharmaceuticals
• Galderma
• Janssen Biotech
• Novartis
• Valeant Pharmaceuticals
• Abeona Therapeutics
• Allergan
• Elorac
• GlaxoSmithKline
• Hexima
• Hisamitsu Pharmaceutical
• Mayne Pharma
• MediQuest Therapeutics
• Meiji Seika Pharma
• Merz Pharma
• Moberg P
  

For more information visit http://www.researchandmarkets.com/research/97bx43/global

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.